| Page 99 | Kisaco Research

INVOKAT Intellectual Property Services

The event was perfectly suitable for the professionals who have expertise in life science. All speakers and attendees were highly qualified and experienced in diverse fields of IP.  

Sanovel

I had the privilege of attending the Life Sciences Strategy Summit 2023, and it was an invaluable experience. The event brought together a diverse and knowledgeable community of professionals, fostering insightful discussions on the latest trends and strategies in the life sciences industry. The engaging sessions and networking opportunities provided a unique platform to connect with experts and peers, contributing to a richer understanding of the field. I'm grateful for the opportunity to be part of this vibrant community, and I look forward to future events. 

Hoffmann Eitle

I have already recommended the event to colleagues. I particularly liked the presentations on the SPC waivers and on the proposals for unitary SPCs and the amended SPC Regulations as well as the national examiners' session. 

TRON

Informative breadth of multidisciplinary topics which are rarely fused together into a single conference elsewhere. Provided useful insights from the perspectives of different domains.

Teva Pharmaceuticals

Excellent speakers and highly relevant topics made for a thoroughly worthwhile conference.

Morphic Therapeutics

The speakers were well coordinated so little overlap but good integration of the topics. I came away with a better understanding of the topics presented. 

Remfry & Sagar

This is a serious conference and was attended by IP attorneys and in house counsels. The topics taken were very relevant and it was a very good experience. The round table discussion was also good.

Norgine

A really well organised event with an excellent selection of relevant talks and great networking opportunities.

NLO

The Summit gave a good overview and an opportunity to hear and discuss the latest insights on IP and exclusivity for Life Science. I liked that all relevant parties were present to share their views. 

Genepharm SA

Good overview of the ongoing challenges and proposals in EU with regards to UPC, SPC and Regulatory, preempting Generics to roll up their sleeves.